Low incidence of abacavir hypersensitivity reaction among african children initiating antiretroviral therapy

Pediatric Infectious Disease Journal

Volumn 30, Issue 6, 2011, Pages 535-537

  Nahirya Ntege, Patricia ^a   Musiime, Victor ^b   Naidoo, Bethany ^c   Bakeera Kitaka, Sabrina ^d   Nathoo, Kusum ^e   Munderi, Paula ^a   Mugyenyi, Peter ^b   Kekitiinwa, Adeodata ^d   Bwakura Dangarembizi, Mutsa F ^e   Crawley, Jane ^c  

^a UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^b JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d MULAGO HOSPITAL   (Uganda)

^e UNIVERSITY OF ZIMBABWE   (Zambia)

Author keywords

abacavir; Africa; children; HIV; hypersensitivity

Indexed keywords

ABACAVIR; COTRIMOXAZOLE; EFAVIRENZ; NEVIRAPINE;

ABDOMINAL PAIN; ADOLESCENT; AFRICAN AMERICAN; ARTICLE; CHILD; CLINICAL FEATURE; CONJUNCTIVITIS; COUGHING; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; EDEMA; ERYTHEMA; ERYTHEMA MULTIFORME; FATIGUE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MACULAR RA; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALAISE; MEDICAL EDUCATION; MORBIDITY; MOUTH ULCER; MYALGIA; PATIENT EDUCATION; PHARYNGITIS; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RASH; SCHOOL CHILD; STOMATITIS; URTICARIA; VOMITING;

EID: 79957994366     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182076864     Document Type: Article

References (10)

1. World Health Organization. Antiretroviral therapy of HIV infection in infants and children: towards universal access. Geneva: World Health Organization; 2006.
2. Hughes CA, Foisy MM, Dewhurst N, et al. Abacavir hypersensitivity reaction: an update. Ann Pharmacother. 2008;42:387-396. (Pubitemid 351429604)
3. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002; 359:1121-1122. (Pubitemid 34270738)
4. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. August 16, 2010; pp 1-219. Available at http://aidsinfo.nih.gov/ contentfiles/PediatricGuidelines.pdf. Pages 151-3 accessed October 10, 2010.
5. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics. 2004;5:203-211. (Pubitemid 38351278)
6. Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46:1111-1118. (Pubitemid 351589880)
7. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568-579.
8. Phillips EJ, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS. 2005;19:979-981. (Pubitemid 40834943)
9. Chui CK, Brumme ZL, Brumme CJ, et al. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. Clin Infect Dis. 2007;44: 1503-1508. (Pubitemid 46801597)
10. Hughes DA, Vilar FJ, Ward CC, et al. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics. 2004;14:335-342. (Pubitemid 38813687)